Use of Nesiritide in the Management of Acute Diastolic Heart Failure
|ClinicalTrials.gov Identifier: NCT00083772|
Recruitment Status : Terminated
First Posted : June 3, 2004
Last Update Posted : July 31, 2012
Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure.
Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure Cardiovascular Disease Acute Heart Failure Diastolic Heart Failure Congestive Heart Failure Heart Disease||Drug: Nesiritide||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Use of Nesiritide in the Management of Acute Diastolic Heart Failure|
|Study Start Date :||May 2004|
|Primary Completion Date :||April 2006|
|Study Completion Date :||April 2006|
Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
Other Name: Natrecor
- Effectiveness of nesiritide in improving symptoms, including pressure in heart and lungs, related to diastolic heart failure (condition where heart muscle is stiff and not able to relax completely, causing the pressures in heart to increase). [ Time Frame: 2 Years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083772
|Study Chair:||Jean-Bernard Durand, MD||UT MD Anderson Cancer Center|